NRC Health

Q2 FY2026 EarningsQ2 FY26 results presented a top-line beat and significant normalized earnings outperformance: revenue of $35.4M vs. $34.9M expected, and Adjusted EPS of $0.31 vs. $0.14 consensus. While GAAP EPS of -$0.15 was in-line with expectations, the reported net loss was primarily driven by a $6.5M non-cash accelerated stock-based compensation charge related to executive leadership transition amendments. Underlying growth remains healthy, with Total Recurring Contract Value (TRCV) increasing 11% YoY to $151.9M, signaling sustained demand for Human Understanding® solutions.